Shire May Split Up – But Punting On Bigger Decisions For Now

The specialty pharma is dividing its operations into rare disease and neuroscience units, but whether that will mean a spinout for the latter won't be revealed for months.

Headed for danger business concept as a man walking on a straight road towards a group of dangerous sharks as a metaphor and symbol of risk and courage from a person on a career path or life journey.

Following through on a strategy it first began talking about last August, Shire PLC announced Jan. 8 that it is creating "two distinct divisions" within the company – one focused on rare diseases, the other on neuroscience – and will begin reporting the operational metrics of each unit starting with its first quarter earnings report.

Intentionally left up in the air is whether Shire is thinking about a spinout or an initial public offering for the smaller neuroscience unit, comprised mainly of its ADHD franchise,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Strategy

All Over For iTeos But Applause For Plan To Return Cash Fast

 
• By 

The company has moved quickly to wind down operations after its anti-TIGIT pact with GSK collapsed.

Loss Of Exclusivity Product Launches To Fuel Aurobindo’s FY26 Europe Growth

 
• By 

Aurobindo is banking on launches of loss of exclusivity products and biosimilars to fuel sales in Europe as it awaits a US announcement on tariffs and predicts high single-digit growth overall during FY26 for now

GSK’s Bet On Spero’s Oral cUTI Antibiotic Poised To Pay Off With New Phase III Data

 
• By 

Spero and partner GSK have Phase III non-inferiority data to support approval of tebipenem as the first oral antibiotic for complicated urinary tract infections.

Roivant Staying ‘Patient’ On Deals, Leaving Investors Waiting

 

CEO Matt Gline talked to Scrip in an interview about dealmaking and the road back to commercialization.

More from Business

GSK’s Bet On Spero’s Oral cUTI Antibiotic Poised To Pay Off With New Phase III Data

 
• By 

Spero and partner GSK have Phase III non-inferiority data to support approval of tebipenem as the first oral antibiotic for complicated urinary tract infections.

Roivant Staying ‘Patient’ On Deals, Leaving Investors Waiting

 

CEO Matt Gline talked to Scrip in an interview about dealmaking and the road back to commercialization.

Bayer Has BI In Its Sights With Priority Review For HER2 Lung Cancer Drug

 
• By 

Sevabertinib gets onto the FDA's approval fast track three months after zongertinib.